Guanine nucleotide exchange factors (GEFs) stimulate guanine nucleotide exchange and the subsequent activation of Rhofamily proteins in response to extracellular stimuli acting upon cytokine, tyrosine kinase, adhesion, integrin, and G-proteincoupled receptors (GPCRs). Upon Rho activation, several downstream events occur, such as morphological and cytoskeletal changes, motility, growth, survival, and gene transcription. The leukemia-associated RhoGEF (LARG) is a member of the regulators of G-protein signaling homology domain (RH) family of GEFs originally identified as a result of chromosomal translocation in acute myeloid leukemia. Using a novel fluorescence polarization guanine nucleotide-binding assay using BODIPY-Texas Red-GTPγS (BODIPY-TR-GTPγS), the authors performed a 10,000-compound high-throughput screen for inhibitors of LARG-stimulated RhoA nucleotide binding. Five compounds identified from the high-throughput screen were confirmed in a nonfluorescent radioactive guanine nucleotide-binding assay measuring LARG-stimulated [ 35 S] GTPγS binding to RhoA, thus ruling out nonspecific fluorescent effects. All 5 compounds selectively inhibited LARG-stimulated RhoA [ 35 S] GTPγS binding but had little to no effect on RhoA or Gα o [ 35 S] GTPγS binding. Therefore, these 5 compounds should serve as promising starting points for the development of small-molecule inhibitors of LARG-mediated nucleotide exchange as both pharmacological tools and therapeutics. In addition, the fluorescence polarization guanine nucleotide-binding assay described here should serve as a useful approach for both high-throughput screening and general biological applications.
INTRODUCTION
T HE RHO-FAmILY OF SmALL GTPASES ARE A mAIn SUBSET of the Ras superfamily of small GTPases (~20-25 kDa). 1 The Rho-family of GTPases is further subdivided into 10 subgroups based on their identity. In this work, we focus on the small GTPase RhoA, which is a member of the Rho subgroup (RhoA, RhoB, and RhoC) within the Rho-family of proteins. In the cell, Rho GTPases are activated upon ligand activation of cell surface receptors, such as cytokine, tyrosine kinase, adhesion, integrin, and G-protein-coupled receptors (GPCRs). 2 As a result, this causes Rho GTPases to switch from their inactive guanine diphosphate (GDP)-bound form to their active guanine triphosphate (GTP)-bound form, leading to various downstream cellular events, such as cytoskeletal and morphological changes, migration, growth, survival, and gene transcription. 1 The activation state of Rho GTPases is controlled by several classes of regulatory proteins. The GTPase-activating proteins (GAPs) catalyze GTP hydrolysis by active Rho proteins, leading to their inactivation. The guanine nucleotide-dissociation inhibitors (GDIs) sequester GDP-bound Rho GTPases in the cytosol, thus preventing their subcellular localization to the plasma membrane and activation. Last, the guanine nucleotide exchange factors (GEFs) stimulate the exchange of GTP for GDP upon Rho GTPases, leading to their activation, and are the focus of this work. There are more than 60 identified human Rho GEFs that specifically activate Rho GTPases. 1 Rho GEFs are characterized by their Dbl homology (DH) (~200 residues) and C-terminal adjacent pleckstrin homology (PH) (~100 residues) domains. DH domains are primarily responsible for catalyzing the guanine nucleotide exchange (GTP for GDP) upon Rho GTPases. 1 PH domains are responsible for membrane localization of Rho GEFs and aid the DH domain in catalysis of guanine nucleotide exchange. 1 The focus of this work is on the leukemia-associated RhoGEF (LARG), which was originally identified as a chromosomal translocation fusion protein to mixed-lineage leukemia (mLL) in a patient with acute myeloid leukemia. 3 LARG is a member of the regulators of the G-protein signaling homology domain (RH) containing the RhoGEF family of proteins (LARG, p115-RhoGEF, PDZ-RhoGEF). 4 This family of Rho GEFs is linked to Rhodependent signaling pathways controlled by heterotrimeric GPCRs coupled to the Gα 12 and Gα 13 subunits, such as the lysophosphatidic acid, bombesin, and thrombin receptors. [4] [5] [6] [7] LARG is an important regulatory protein in several clinical disorders. Considering its original identification in acute myeloid leukemia, LARG largely has been thought to be a key player in cancer progression. In conjunction with the Raf-1 kinase, LARG has been shown to transform mouse fibroblasts. 8 It has also been shown to play a role in cell migration and growth of head and neck squamous cancer cells through adhesion and tyrosine kinase receptor interaction and subsequent RhoA activation. 9 LARG has also been shown, through overexpression and siRnA knockdown, to play a role in thrombin and bombesin receptor-mediated prostate cancer cell morphology changes and migration. 6, 7 In addition to cancer, LARG has been implicated in lectin signaling in dendritic cells, which is important in the sequestration of human immunodeficiency virus (HIV) virions leading to the progression of the HIV disease. 10 LARG also has been shown to play a role in vascular biology and calcium signaling. It has been directly linked to a role in salt-induced hypertension in transgenic mice, and it has been speculated to play a role in erectile dysfunction. [11] [12] [13] As a result, considering the implication of LARG in multiple diseases and disorders, it is an attractive molecular target for drug discovery.
Currently, there are limited pharmacological tools targeting RhoGEFs and RhoGTPases. To date, most of the efforts have focused on inhibiting the lipid modification of RhoGTPases, which is necessary for plasma membrane localization and activation. The inhibitors of this modification include farnesyltransferase and geranylgeranyl transferase inhibitors and the cholesterol-lowering statin drugs. 14, 15 Unfortunately, these inhibitors and drugs are not specific to RhoGTPases, which complicates the mechanistic interpretation of results using these inhibitors. To date, there are only 2 reported specific inhibitors of RhoGTPases. Both inhibitors selectively inhibit Rac1, but they differ in their mechanism of inhibition. The inhibitor nSC23766 (IC 50 , ~50 µm) inhibits by binding to the GEF binding pocket on Rac1, 16 Therefore, in this study, we performed a 10,000-compound high-throughput screen for small-molecule inhibitors of LARGstimulated RhoA nucleotide exchange. To do this screen, we first developed a novel fluorescence polarization (FP) RhoA nucleotide-binding assay using BODIPY-TR-GTPγS. We chose fluorescence polarization rather than both the standard fluorescence intensity and radioactive [ 35 S] GTPγS binding approaches because it proved to be more environmentally friendly, robust, reliable, and reproducible. Of the 10,000 compounds screened, 6 were confirmed to inhibit LARG-mediated guanine nucleotide exchange. Of these 6 compounds, 5 were confirmed in a nonfluorescent, radioactive [ 35 S] GTPγS guanine nucleotide-binding assay with IC 50 values in the micromolar range. These compounds showed selectivity for LARG-stimulated RhoA [ 35 S] GTPγS binding by having little to no effect on RhoA and Gα o [ 35 S] GTPγS binding. Therefore, as a result of the high-throughput screen with this novel FP guanine nucleotide-binding assay, 5 promising compounds were identified as inhibitors of LARGstimulated RhoA nucleotide binding. Therefore, with further synthetic chemistry follow-up, these compounds may lead to useful inhibitors of LARG-stimulated RhoA nucleotide binding for both research and therapeutic purposes.
MATERIALS AND METHODS

Plasmids, protein purification, and chemical reagents
Human RhoA (residues 1-189, C189S) was expressed in Escherichia coli as described previously. 19 Human LARG encoding the DH/PH domains (residues 765-1138) was expressed in E. coli as described previously. 20 Gα o expression and purification in E. coli was described previously. 21 BODIPY Texas Red (TR) guanosine 5′-O-(3-thiotriphospahte) (GTPγS) was obtained from molecular Probes-Invitrogen (Eugene, OR). [ 35 S] GTPγS was obtained from PerkinElmer (Waltham, mA). GTPγS was obtained from EmD Biosciences (San Diego, CA). The nonionic detergents IGEPAL and Lubrol were from Sigma (St. Louis, mO). The 10,000 structurally diverse chemical compounds were obtained from ChemBridge (San Diego, CA) as part of the collection of the University of michigan Center for Chemical Genomics (CCG). The chemical similarity was low: at 80% similarity calculated with the ICmPro (molsoft LLC, La Jolla, CA) clustering algorithm, there were 4390 clusters with a median size of 1 compound and mean size of 2.28 compounds.
Guanine nucleotide-binding FP assays
Exchange buffer (20 mm Tris HCl [pH 7.5], 150 mm naCl, 10 mm mgCl 2 , 10% glycerol, 0.01% IGEPAL, and freshly prepared 1 mm DTT) was added to each well of a black 96-well plate. Purified full-length human RhoA(C189S), purified DH/PH domain of human LARG, and BODIPY-FL-GTPγS or BODIPY-TR-GTPγS were added sequentially to each well to a final volume of 100 µL per well. Fluorescein or Texas Red fluorescence polarization was read in a Victor 2 plate reader using excitation at 485 nm and emission at 535 nm for fluorescein or an excitation at 560 nm and emission at 630 nm for Texas Red. The measured values of polarization (mP) were calculated by using the following formula: mP = (F || -F ⊥ )/(F || + F ⊥ ), where F || = fluorescence intensity parallel to the excitation plane, and F ⊥ = fluorescence intensity perpendicular to the excitation plane. The statistical Z′ factor used to assess assay suitability for high-throughput screening (HTS) was calculated by using the following formula: Z′ = 1 -[(3σ c+ + 3σ c-)/ (|µ c+ -µ c-|)], where σ = standard deviation, µ = mean, c + = with LARG, and c -= without LARG.
RhoA [ 35 S] GTPγS guanine nucleotide-binding assay
The indicated concentrations of the purified DH/PH domain of human LARG (0.5-2 nm, final) were added to a tube in buffer I (20 mm Tris [pH 7.5], 1 mm EDTA, 1 mm DTT, 50 mm naCl, 0.1% Lubrol, 2 mm mgCl 2 ) in a final volume of 180 µL. To this mixture, 45 µL of purified human RhoA (C189S) in buffer I was added to yield a final concentration of 500 nm. The reaction was initiated by adding 225 µL of 2× binding buffer (100 mm Tris [pH 7.5], 1 mm EDTA, 2 mm DTT, 100 mm naCl, 10 mm mgCl 2 , 5 µm GTPγS, 0.1% Lubrol, 6.75 µCi [ 35 S] GTPγS) for a final reaction volume of 450 µL. Reaction mixtures were incubated at room temperature for 1, 5, 10, 30, 60, 120, and 180 min. Then, 50 µL of reaction mixture was removed and diluted in a tube containing 4 mL of ice-cold wash buffer (20 mm Tris [pH 8.0], 100 mm naCl, 25 mm mgCl 2 ) to stop the reaction. An additional 4 mL of wash buffer was added to the tube and the sample filtered on a BA85 25-mm nitrocellulose filter using a Hoeffer filtration system. Filters were washed 2 times with 4 mL of wash buffer. Filters were dried under a heat lamp for 5 min. Filters were counted in 4 mL of scintillation fluid (Scintiverse, Fisher Scientific, Hampton, nH) for 1 min using a Beckman LS 5801 Scintillation Counter. The identical method was followed for RhoA [ 35 S] GTPγS binding studies without LARG, except reaction mixtures were incubated at room temperature for 1, 5, 10, 30, 60, 130, and 180 min.
Gα o [ 35 S] GTPγS guanine nucleotide-binding assay
Purified Gα o was diluted to a final concentration of 10 µm in 180 µL of Gα o dilution buffer ( Then, 40 µL of the reaction mixture was diluted in a tube containing 4 mL of ice-cold wash buffer (20 mm Tris [pH 8.0], 100 mm naCl, 25 mm mgCl 2 ). This reaction mixture was then filtered on a BA85 25-mm nitrocellulose filter using a Hoeffer filtration system. Filters were washed twice with 4 mL of wash buffer, then dried under a heat lamp for 5 min. Filters were counted in 4 mL of scintillation fluid for 1 min using a Beckman LS 5801 Scintillation Counter.
High-throughput LARG-stimulated RhoA guanine nucleotide-binding FP screen
Using a multidrop 384 (Thermo Scientific, Waltham, mA), exchange buffer was added to each well of a low-volume black 384-well plate (cat. 3676, Corning, nY); 20 µL was added for the positive control wells (i.e., no LARG), and 15 µL was added to all other wells. Using a 384-well pin tool on a Biomek FX liquid-handling workstation (Beckman Coulter, Fullerton, CA), approximately 250 nL of compound (stock concentration 0.75-4 mm; ChemBridge) or DmSO, for control wells, was added (producing final compound concentrations of ~6-30 µm and 0.8% DmSO). Plates were then incubated at room temperature for 5 min. Using a multidrop micro (Thermo Scientific), 5 µL of purified DH/PH domain of human LARG in exchange buffer was added to the wells of the 384-well plate to produce a final concentration of 100 nm. Plates were then incubated for 5 min at room temperature. Using a multidrop micro, 5 µL of purified human RhoA (C189S) in exchange buffer was added to produce a final concentration of 2 µm. Plates were then incubated for 2 min at room temperature. The reaction was initiated by using a multidrop micro to add 5 µL of BODIPY-TR GTPγS in exchange buffer to a final concentration of 500 nm and a final reaction volume of 30 µL. Plates were incubated for 20 min at room temperature, then read for fluorescence polarization with a PHERAstar (BmG LabTech, Offenburg, Germany) plate reader with a 575-nm band pass excitation filter, a 620-nm band pass emission filter, a dichroic mirror, and a dual-emission beam splitter to permit simultaneous recording of parallel and perpendicular fluorescence readings. Plates were individually incubated after each addition so that all plates would be read in the PHERAstar plate reader precisely at 20 min after GTPγS addition (i.e., prior to saturation of the reaction time course). For follow-up dose-response studies of the primary hits, the same method was carried out as for the high-throughput screen, except reagents were added by hand with a multichannel pipet. In addition, compounds were added to the wells of the 384-well plate using serial 2-fold dilutions over a range of concentrations between 100 µm and 3.125 nm.
Compound properties
Compound properties were calculated with ChemAxon JChem software. The LogP value method is described in Viswanadhan et al. 22 
RESULTS
FP guanine nucleotide-binding assay
To study RhoA guanine nucleotide exchange in vitro, we used a novel FP guanine nucleotide-binding assay adapted from the standard fluorescence intensity guanine nucleotidebinding assay described previously by our laboratory. 23, 24 This FP assay uses the nonhydrolysable fluorescently labeled guanine nucleotide BODIPY-GTPγS fluorophores. LARGstimulated BODIPY-GTPγS fluorophore binding to RhoA results in fluorescence polarization that can be read by a plate reader (Fig. 1A) . The structures of the BODIPY-GTPγS fluorophores used in this study are shown in Figure 1C .
Due to the importance of having a robust and reproducible assay for HTS, we compared the suitability of nucleotide binding to RhoA measured by fluorescence intensity (data not shown) versus fluorescence polarization (Fig. 2) . Although both intensity and polarization assays gave signals for RhoA nucleotide binding, only the FP assay (Z′ factor = 0.7) gave suitably reproducible data appropriate for doing HTS (Fig. 2) . The FP assay takes into account fluorescence that is both parallel and Evelyn et al. perpendicular to the excitation plane, and the ratiometric nature of the measurement cancels many contributions to the noise. 25 This most likely accounts for the difference between the Z′ factors of the 2 assays. As a result, fluorescence polarization should be a useful assay for HTS for small-molecule inhibitors of GEFstimulated small GTPase guanine nucleotide binding. In addition, the assay has recently been used for general biological applications studying GEF activity upon small GTPases. 26
Bodipy-FL-GTP
Comparison between the FP and [ 35 S] guanine nucleotide-binding assays
The standard [ 35 S] GTPγS nucleotide-binding assay is generally not suitable for HTS due to time consumption, accumulation of environmental hazardous waste, and the complexity of adapting the assay to a 384-well plate format. Therefore, we chose the FP assay to use for our high-throughput screen. We found that in both assays, LARG was able to stimulate RhoA (C189S) nucleotide binding in a concentration-dependent manner (Fig. 3A, B) . However, the time courses for saturation in the 2 methods differed, with saturation occurring at 40 min for the FP assay and 180 min for the [ 35 S] radioactive assay. The basal rate constant for nucleotide exchange was slower with the [ 35 S] GTPγS method. The faster kinetics of binding in the FP assay may be due, in part, to higher concentrations of RhoA and nucleotide, the lower amount of nucleotide relative to the amount of RhoA, the higher naCl or mgCl 2 concentrations, or the nonnative BODIPY nucleotide structure in the FP assay. However, plotting the rate constants on a graph both give a linear plot (Fig. 3C, D) , suggesting that both the FP and radioactive nucleotide-binding assays are appropriate for measuring GEFstimulated nucleotide binding to the Rho-family of proteins.
High-throughput screen for inhibitors of LARG-stimulated RhoA nucleotide exchange
A 10,000 diverse chemical compound collection from ChemBridge was used to screen for small-molecule inhibitors of LARG-stimulated RhoA nucleotide exchange. The FP guanine nucleotide-binding assay using the purified DH/PH domain of LARG and RhoA (C189S) was used for the screen. Compounds were added to a black 384-well low-volume plate containing exchange buffer with a 384-well pin tool on the Biomek FX workstation. Then, the purified DH/PH domain of LARG, RhoA (C189S), and BODIPY-TR-GTPγS was added to the plate in sequential order. After a 20-min incubation (nonsaturating time point), polarization was read in a PHERastar plate reader, as shown in Figure 4A . The assay was tested for its suitability for HTS and reliability by using the Z′ factor statistical measurement. Using purified RhoA (C189S) alone plus DmSO (positive control for screen-100% inhibition) and the purified DH/PH domain of LARG and RhoA (C189S) plus DmSO (negative control for the screen-0% inhibition), the Z′ factor in this HTS format was determined to be 0.52, indicating a suitable and reliable screen (Fig. 4B) . 27 Although many FP-type screens give higher Z′ factors than this, consideration should be taken of the fact that this is a kinetic assay done at a presaturation time point, so it would not be expected to have quite as good a Z′ as a standard equilibrium FP binding assay.
Compounds that showed more than 30% inhibition or values of percent inhibition more than 3 standard deviations from the negative control were considered to be actives. Figure 4C shows 19 hits from the 30% inhibition criterion, and an additional 12 were found with the 3 standard deviation criterion, providing 31 initial actives (or a "hit" rate of 0.3%). There were several plates with clusters of compounds that just met the cutoff, and they were retested in duplicate using the primary screening assay methodology. Any that confirmed in either of the 2 measurements were retained in the actives list and were studied further in a concentration response study using the BODIPY-TR-GTPγS FP assay. Of those 13 compounds, 7 (0.07% hit rate) did inhibit in this follow-up assay, and 6 compounds did not (<50% inhibition at 100 µm; Fig. 4D ). Of the 7 confirmed actives, 6 were available for resupply from ChemBridge for follow-up studies. Fig. 4D and Table 1 ) in the FP assay.
LARG-Mediated Nucleotide Exchange Inhibitors
Secondary screen in [ 35 S] GTPγS radioactive guanine nucleotide-binding assay
As mentioned previously, a potential mechanism for false positives in a fluorescence-based assay is quenching of the fluorescence signal. To address this concern, we used the traditional Evelyn et al. Figure 5A . Five of the 6 candidate compounds showed dose-dependent inhibition in the [ 35 S] GTPγS guanine nucleotide-binding assay. The 1 compound that was not active in the radioligand assay showed a marked effect on the total fluorescence, as calculated by F parallel + 2*F perpendicular (54% reduction). The 3 most potent compounds in this radioactive-based assay-CCG-13528, CCG-14631, and CCG-7167-had IC 50 values between 4 and 7 µm ( Fig. 5B and Table 1 ). The other 2 compounds, CCG-14113 and CCG-12529, were less potent, with IC 50 values around 30 µm ( Table 1) compounds differ between the [ 35 S] GTPγS and fluorescence polarization methods. These differences most likely can be attributed to experimental differences between the assays such as naCl and mgCl 2 concentrations and the different nature of the detergent or nucleotide used. Despite these differences, the fact that 5 of the 6 tested compounds did show some activity in the [ 35 S] GTPγS method is encouraging. CCG-13528 and CCG-14631 satisfy all of Lipinski's rulesof-5 for chemical compounds that have the most potential in becoming a drug with respect to their physical properties. 28 CCG-7167 had only 1 violation of Lipinski's rule-of-5 due to a partition coefficient (log P) of 5.52 ( Table 1) . Interestingly, our 3 most potent compounds are all extended aromatic molecules. They have 4 (CCG-14631) or 5 (CCG-13528, CCG-7167) rings and are 16 (CCG-13528) or 18 (CCG-14631, CCG-7167) atoms in length (Fig. 5C) . This suggests a potential pharmacophore for inhibiting LARG-stimulated RhoA nucleotide exchange, which may be explained by the long shallow pocket of the LARG-RhoA interaction site. 29
Compound selectivity for LARG-stimulated RhoA nucleotide binding
Inhibition of LARG stimulation of RhoA nucleotide exchange can occur by 2 primary mechanisms. The compound could directly inhibit GTP binding to RhoA, or it could block LARG-mediated nucleotide exchange. Determining the exact mechanism of the inhibition of LARG-stimulated RhoA nucleotide exchange is beyond the scope of the present study, but we did determine whether the compounds inhibited GTP binding or LARG-mediated exchange in the [ 35 S] GTPγS guanine nucleotide-binding assay. [ 35 S] GTPγS binding to the small GTPase RhoA and the G-protein alpha subunit Gα o was determined at 60 min and 25 min, respectively (Fig. 6A, B) . GTPγS binding at a maximal concentration of 100 µm (Fig. 6C) . Therefore, the 5 compounds identified in the high-throughput screen described here do appear to inhibit the LARG-mediated nucleotide exchange in some manner.
DISCUSSION
Radioactive and fluorescence assays are the primary approaches used to measure guanine nucleotide exchange of small GTPases. These approaches typically use radioactive [ 3 H] or [ 35 S] or fluorescent n-methyl-3′-O-anthranoyl (mAnT) and boron dipyrromethene (BODIPY) analogs of guanine nucleotides. They either measure binding of the nonhydrolysable GTP analog, GTPγS, to G-proteins or release of labeled GDP from G-proteins. 23, 24, 30 Upon nucleotide exchange, the guanine nucleotide analogs yield either a measurable radioactive or fluorescence signal. Here, we describe a novel assay that uses fluorescence polarization rather than the standard fluorescence intensity approach to measure LARG-stimulated RhoA nucleotide binding. We chose the FP assay due to its better, initial baseline kinetics, signal-to-noise ratio, and Z′ factor (data not shown). The Z′ factor measures the reliability of a positive screening hit based on the dynamic range and intrinsic variability of the assay. 27, 31 The Z′ factor for the FP assay was 0.7 in pilot studies and showed a sustained level of 0.52 in our 10,000-compound screen. This should be sufficient for HTS and for general biological applications.
One major issue in fluorescence-based HTS assays is the type of fluorophore one chooses. The most commonly used fluorophores used to label guanine nucleotides, mAnT and BODIPY-FL, have the drawback of being detected in the blue and green regions of the electromagnetic spectrum. 32 This enhances the chance of false positives in high-throughput screens due to compounds absorbing light in this region of the electromagnetic spectrum. Therefore, in the work described here, we use a GTPγS nucleotide labeled with the BODIPY-TR fluorophore (Fig. 1C) , which is detected in the red region of the electromagnetic spectrum. This, along with the use of the ratiometric FP method, should decrease the chance of false positives due to nonspecific compound absorbance. We compared the FP BODIPY-TR-GTPγS binding assay as a measure of nucleotide exchange with the traditional radioactive [ 35 S] GTPγS binding assay. We found both assays to be able to show concentration-dependent LARG-stimulated RhoA nucleotide binding and linear rate constants with respect to LARG concentration (Fig. 3) . However, the 2 methods were different with respect to experimental conditions (i.e., buffers, protein concentrations, type of detergent and nucleotide) and reaction time. Despite the differences between assays, we chose the fluorescence polarization assay for a high-throughput screen for inhibitors of LARGmediated nucleotide exchange based on its reliability, adaptability to a 384-well plate format, lack of production of environmental waste, and time efficiency.
There are several ways that one can molecularly target the function of RhoGEFs and RhoGTPases. One can inhibit the membrane localization of RhoGTPases through blockade of lipid modifications. Interestingly, using an HTS approach, Peterson et al. 33 describe the identification of a geranylgeranyl transferase type I small-molecule inhibitor (IC 50 , 10 µm) that inhibits RhoGTPase function. Another way to obstruct Rho function is through small-molecule stimulation of GAPs to stimulate intrinsic hydrolysis of RhoGTPases, promoting inhibition of function. Small-molecule stabilization of the association of GDP dissociation inhibitors (GDIs) with RhoGTPases can also be effective in disrupting the activation of RhoGTPases by preventing membrane localization. 1 Also, small-molecule inhibition of GEFs would be effective in disrupting Rho function by preventing activation of RhoGTPases. Function can be abolished by directly targeting the RhoGTPase. Interestingly, Gao et al. 16 describe the identification of a direct small-molecule inhibitor of Rac1, nSC23766 (IC 50 , 50 µm), through a structurebased virtual screening approach. Another direct Rac1 inhibitor, EHT 1864 (K d , 40 nm), selectively inhibits Rac1 through blocking the binding of the guanine nucleotide to Rac1. 17, 18 Also, we recently identified an inhibitor downstream in the Rho-stimulated gene transcription pathway using a cell-based luciferase reporter screen. 34 As a result, we describe here a FP high-throughput screen of a ChemBridge diverse chemical library for inhibitors of LARG-mediated RhoA nucleotide exchange. LARG was originally discovered as a chromosomal translocation fusion to mLL in a patient with acute myeloid leukemia. 3 Therefore, from its initial identification, LARG has been linked to cancer. LARG gene expression was shown to be upregulated in patients with the preleukemic disorder Scwachman-Diamond syndrome (SDS). 35 LARG was first shown to have oncogenic activity in a nIH3T3 transformation assay. 8 Since then, LARG-mediated Rho activation has been shown to be important in prostate cancer (PC-3) and breast cancer (mDA-mB-435) cell morphology, motility, and invasion upon extracellular stimulation by the GPCR ligands bombesin, thrombin, and lysophosphatidic acid. 6, 7, 36 In addition, LARG interaction with the adhesion receptor, CD44, or tyrosine kinase receptor, epidermal growth factor receptor (EGFR), and subsequent Rho activation has been shown to be necessary for cytoskeletal modification, motility, and invasion in head and neck squamous cell carcinoma (HSC-3) cells. 9 Therefore, a small-molecule inhibitor of LARG-mediated RhoA nucleotide exchange would be a useful tool to elucidate cancer mechanisms and as a potential cancer therapeutic. In addition to cancer, LARG also has the potential to play an important role in HIV or vascular diseases. LARG has been shown to be upregulated in rat vascular smooth muscle by angiotensin II, and it is basally expressed in rat corpus cavernosum, Evelyn et al. thus potentially playing a vital role in contraction and calcium sensitization. 11, 13, 37 Recently, LARG was determined to be the key RhoGEF involved in the development of salt-induced hypertension. 12 Interestingly, Hodges et al. 10 describe a role for LARG in HIV-1 pathogenesis via forming a complex with the c-type lectin receptor, DC-SIGn. Therefore, small-molecule inhibition of LARG-mediated RhoA nucleotide exchange may prove to be useful in the development of pharmacological tools and therapeutics for better understanding of disease pathogenesis and treatment of diseases and disorders, including HIV, hypertension, and erectile dysfunction (ED). The 5 compounds identified in this study would be of interest for further development based on the multiple diseases and disorders that an inhibitor of LARG-mediated RhoA nucleotide exchange may have a positive impact on. All 5 compounds have potency in the micromolar range, which make them reasonable candidates for synthetic chemistry follow-up. In addition, the compounds do not inhibit GTP binding to RhoA or to Gα o . Therefore, they most likely inhibit LARG-mediated nucleotide binding by (1) binding to the LARG binding surface on RhoA; (2) binding to the RhoA binding surface on LARG; (3) allosterically binding to either LARG or RhoA, causing a conformational change; (4) binding to both RhoA and LARG; or (5) covalently modifying RhoA or LARG. Further development, specificity studies, and mechanistic characterization are still needed, but the compounds identified in this study inhibit LARG-mediated RhoA nucleotide exchange with micromolar potency in vitro.
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